Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study.
J Infect
; 85(3): 334-363, 2022 09.
Article
in En
| MEDLINE
| ID: mdl-35659547
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HIV Infections
/
HIV-1
/
HIV Protease Inhibitors
/
Anti-HIV Agents
/
HIV Fusion Inhibitors
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
J Infect
Year:
2022
Document type:
Article
Affiliation country: